The global entacapone market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Entacapone is used by combining with levodopa/carbidopa for the treatment of the end-of-dose "wearing-off" effect in patients with Parkinson's disease. Parkinson's disease is a disorder of the central nervous. It is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. The major factor for the growth of the market is the increasing prevalence of Parkinson disease.

According to the Parkinson Foundation, almost one million people are living with Parkinson disease in the US which is expected to rise to 1.2 million in 2030. Additionally, approximately 60,000 Americans are diagnosed with PD each year and more than 10 million people are living with PD globally. Further, PD disease increases with age however, an estimated 4% of people with PD are diagnosed before age 50. Moreover, the prevalence of PD in men are 1.5 times as compared to women. However, increasing cost for the treatment of PD is hampering the growth of the global entacapone market during the forecast period.

Some major key players in the market include Novartis International AG, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, STADA declared European launch of the Lecigon triple-combination of levodopa, carbidopa, and entacapone for treating advanced Parkinson's disease. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape-Novartis International AG, Teva Pharmaceutical Industries Ltd.,and Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Entacapone Market Report by Segment

By Product 

• Purity:98%

• Purity: above 98%

By Application 

• Tablet Product

• Capsule Product

• Others

Global Entacapone Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa